Skip to content

MiR‑204‑5p modulates glial morphology and apomorphine‑induced rotational asymmetry without dopaminergic neuroprotection in a preclinical mouse model of Parkinson’s disease

Oct 2026 · Metabolic brain disease · Vol 41 · 0 citations · 71 references
Medicine

TL;DR

Findings indicate that miR‑204‑5p mimic administration can modulate glial morphology and apomorphine‑induced rotational asymmetry in a severely denervated nigrostriatal system without detectable dopaminergic neuroprotection as assessed by TH immunostaining.

View source

Similar papers

Open access Sep 2026

Therapeutic Potential of iPSC-Derived TH⁺/FOXA2⁺ Neuronal Extracellular Vesicles in Parkinson’s Disease Revealed by Organoid and Rodent Models

Background Parkinson’s disease (PD) is characterized by the progressive loss of midbrain dopaminergic (DA) neurons and aberrant α-synuclein (α-syn) aggregation, yet disease-modifying therapies that simultaneously retard neurodegeneration and foster regeneration remain lacking. Methods In this study, we isolated extrace...

Zhen Qi, Xiao-Wen Li, Xiao Jin et al. · 0 citations
Oct 2026

Norepinephrine modulates the microglial response and protects against MPTP-induced Parkinson's disease pathology through regulation of the PI3K/AKT/mTOR pathway.

AIMS Norepinephrine (NE) deficiency is an early and prominent feature of Parkinson's disease (PD), but its specific contributions to pathogenesis have not been fully elucidated. This study aims to determine whether NE exerts neuroprotective effects in PD models through the modulation of autophagy and microglial activat...

Huan Yin, Dan Zhao, Yun-Fu Wang · 0 citations
Open access Oct 2026

Pharmacological inhibition of REV-ERBα ameliorates motor deficits in the 6-OHDA-lesioned mouse model of Parkinson’s disease

ABSTRACT Parkinson’s disease (PD) is characterized by nigrostriatal dopaminergic (DAergic) degeneration and motor dysfunction. Many PD patients also show circadian rhythm disturbances. Increasing evidence links circadian clock dysfunction to PD pathology. REV-ERBα is a circadian nuclear receptor that regulates DAergic...

Jeongah Kim, M. Choe, Sangwon Jang et al. · 0 citations
Sep 2026

AA-2βG attenuates nigrostriatal degeneration and related dopaminergic, redox, and inflammatory alterations in experimental parkinsonism.

Parkinson's disease (PD) is characterized by progressive nigrostriatal degeneration, dopamine depletion, and interactions among neuronal vulnerability, oxidative imbalance, and neuroinflammatory responses. AA-2βG is a chemically stable ascorbate derivative; however, its protective profile in experimental parkinsonism r...

Wei-Lei Ma, Le-Ping Yan, Jian-Hua Ding et al. · 0 citations
Open access Nov 2026

Histamine-Induced Peripheral Priming Promotes Region-Specific Glial Remodelling and Protects Against Dopaminergic Injury in a Mouse Model of Parkinson’s Disease

Peripheral immune priming can induce long-lasting changes in brain innate immune responses. In neurological diseases, including Alzheimer’s disease and stroke, inflammatory priming has been associated with neuroprotection, likely through microglial reprogramming. Here, we evaluated whether repeated peripheral histami...

Ana Vale, Catarina Serra-Almeida, J. Valero et al. · 0 citations
Open access Sep 2026

Oral sodium butyrate alleviates motor deficits and dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson’s disease rat model

This model indicates the therapeutic potential of oral NaB and provides a translational framework for investigating the mechanisms of NaB therapy in PD and associated neurological disorders and alleviated motor and non-motor deficits in rats with 6-OHDA-induced PD.

Shun-Tai Yang, Yang-Ching Chen, Tzu-Jen Kao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.